SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Huggins C, Hodges CV. Studies on prostate cancer. 1. The effects of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941; 1: 293297.
  • 2
    Huggins C, Stevens RE, Hodges CV. Studies on prostate cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg. 1941; 43: 209223.
  • 3
    Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol. 1997; 79: 235246.
  • 4
    Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999; 341: 17811788.
  • 5
    Eisenberger MA, Walsh PC. Early androgen deprivation for prostate cancer? N Engl J Med. 1999; 341: 18371838.
  • 6
    Wasson JH, Fowler FJ Jr., Barry MJ. Androgen deprivation therapy for asymptomatic advanced prostate cancer in the prostate specific antigen era: a national survey of urologist beliefs and practices. J Urol. 1998; 159: 19931996.
  • 7
    Chodak GW. Editorial comment: androgen deprivation therapy for asymptomatic advanced prostate cancer in the prostate specific antigen era: a national survey of urologist beliefs and practices. J Urol. 1998; 159: 19961997.
  • 8
    Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostatic cancer. Evidence Report/Technology Assessment. Agency for Health Care Policy and Research, 1999.
  • 9
    Seidenfeld J, Samson DJ, Hasselblad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med. 2000; 132: 566577.
  • 10
    Fowler FJ Jr., Barry MJ, Lu-Yao G, Roman A, Wasson J, Wennberg JE. Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988–1990 (updated June 1993). Urology. 1993; 42: 622629.
  • 11
    Fowler FJ Jr., Barry MJ, Lu-Yao G, Wasson JH, Bin L. Outcomes of external-beam radiation therapy for prostate cancer: a study of Medicare beneficiaries in three surveillance, epidemiology, and end results areas. J Clin Oncol. 1996; 14: 22582265.
  • 12
    Barry MJ, Fowler FJ Jr., O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK. Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of The American Urological Association. Med Care. 1995; 33 (4 Suppl): AS145AS155.
  • 13
    Fowler FJ Jr., Barry MJ. Quality of life assessment for evaluating benign prostatic hyperplasia treatments. An example of using a condition-specific index. Eur Urol. 1993; 24 (Suppl 1): 2427.
  • 14
    O'Leary MP, Fowler FJ Jr., Lenderking WR, et al. A brief male sexual function inventory for urology. Urology. 1995; 46: 697706.
  • 15
    Berwick DM, Murphy JM, Goldman PA, Ware JE Jr., Barsky AJ, Weinstein MC. Performance of a five-item mental health screening test. Med Care. 1991; 29: 169176.
  • 16
    Brook RH, Ware JE Jr., Davies-Avery A, et al. Overview of adult health measures fielded in Rand's health insurance study. Med Care. 1979; 17 (7 Suppl): iii-x, 1–131.
  • 17
    Clark JA, Wray N, Brody B, Ashton C, Giesler B, Watkins H. Dimensions of quality of life expressed by men treated for metastatic prostate cancer. Soc Sci Med. 1997; 45: 12991309.
  • 18
    Ware JE Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992; 30: 473483.
  • 19
    Herr HW, O'Sullivan M. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol. 2000; 163: 17431746.
  • 20
    Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999; 281: 15911597.
  • 21
    Pisansky TM, Kozelsky TF, Myers RP, et al. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol. 2000; 163: 845850.
  • 22
    Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol. 2000; 163: 16321642.